| Not Yet Recruiting | To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia Androgenetic Alopecia (AGA) | Phase 2 / Phase 3 | 2024-10-15 |
| Completed | To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chi Alopecia, Male Pattern Hair Loss | Phase 2 | 2023-04-13 |
| Completed | Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029 Androgenetic Alopecia, Acne Vulgaris | Phase 1 | 2022-02-10 |
| Completed | To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia Alopecia, Male Pattern Hair Loss | Phase 2 | 2022-01-31 |
| Unknown | Phase III Study of KX-826 With Adult Male Patients With AGA Androgenetic Alopecia | Phase 3 | 2021-12-29 |
| Unknown | A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors Solid Tumor | Phase 1 / Phase 2 | 2021-11-02 |
| Terminated | A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects Covid19 | Phase 3 | 2021-09-30 |
| Terminated | A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safet COVID-19 | Phase 3 | 2021-08-04 |
| Unknown | GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma Hepatocellular Carcinoma, HCC | Phase 2 | 2021-08-01 |
| Completed | To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects Acne, Alopecia | Phase 1 | 2021-07-25 |
| Completed | Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness Efficacy and Safety | Phase 3 | 2021-03-05 |
| Completed | Phase II Study Evaluating the Efficacy and Safety of KX-826 Androgenetic Alopecia (AGA) | Phase 2 | 2020-09-28 |
| Completed | the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascen Androgenetic Alopecia | Phase 1 | 2020-01-14 |
| Completed | The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 2 | 2019-05-30 |
| Completed | Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) Metastatic Hepatocellular Carcinoma, HCC, Combinations of Drugs; Dependence | Phase 1 / Phase 2 | 2019-05-25 |
| Completed | Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Followi Androgenetic Alopecia | Phase 1 | 2019-01-28 |
| Completed | Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Metastatic Breast Cancer | Phase 1 | 2017-09-06 |
| Completed | Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Phase 1 | 2016-02-10 |